[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Lung cancer is the leading cause of cancer-related death throughout the world including Japan. During the 1990s, new cytotoxic agents such as irinotecan, paclitaxel, docetaxel, vinorelbine, gemcitabine, and amrubicin showed impressive single-agent activity in patients with lung cancer. To date, clinical research has defined the current standard chemotherapy for advanced non-small cell lung cancer (NSCLC) as modern platinum-based doublets considered more efficacious than any single regimen and with no added benefit to triplet therapies. However, we have reached an efficacy plateau with these agents. Rearrangement of the drug combination or change of the drug doses and schedules will not result in significant further progress. New, less toxic agents that improve survival and quality of life are clearly needed. In the last three decades, we have gained a growing understanding of the molecular biologic changes and the complex series of cellular signals that allow cancer cells to manifest behavior. This provides an opportunity to develop novel therapies aimed at inhibiting some of these changes and signals. Targeted agents, primarily the epidermal growth factor receptor inhibitors, have led to a new era in the treatment of NSCLC. This paper will review the current status of cytotoxic agents and molecular targeted therapy in lung cancer potential useful in the treatment of the patients.
Yokoba
Masanori
M
Dept. of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Yanase
Nobuo
N
Masuda
Noriyuki
N
D018943:Anthracyclines / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000068258:Bevacizumab; D001897:Boronic Acids; D000069286:Bortezomib; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D000069347:Erlotinib Hydrochloride; D005663:Furans / Q000627:therapeutic use; D000077156:Gefitinib; D005971:Glutamates / Q000627:therapeutic use; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010094:Oxonic Acid / Q000627:therapeutic use; D000068437:Pemetrexed; D011719:Pyrazines; D011725:Pyridines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D005641:Tegafur / Q000627:therapeutic use; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine; D000093542:Gemcitabine
D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001897:Boronic Acids; D004338:Drug Combinations; D005663:Furans; D005971:Glutamates; C470405:N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine; D011719:Pyrazines; D011725:Pyridines; D011799:Quinazolines; D000068437:Pemetrexed; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D000068258:Bevacizumab; D014747:Vinblastine; D010094:Oxonic Acid; D006147:Guanine; D000069286:Bortezomib; D000077146:Irinotecan; C055866:amrubicin; D000069347:Erlotinib Hydrochloride; D000068818:Cetuximab; D000077235:Vinorelbine; D000077156:Gefitinib; D002166:Camptothecin; D000093542:Gemcitabine